Pacific GeneTech Adjuvant Technology Approved for Use With
Medion Vaccine in Indonesia
HONG KONG, 1 June, 2020 (Newswire.com)
Pacific GeneTech (PGT), a biologics company that develops and commercializes next-generation vaccines, received an Indonesian approval for its patented “Hercules” adjuvant for use with Medion’s coryza poultry vaccine. Medion is a leading Indonesian animal health company with distribution throughout SE Asia.
Adjuvants are added to vaccines to enhance immune response to antigens. “Hercules is designed to be particularly effective in boosting mucosal immunity in orally or nasally administered vaccines, but it can also be used effectively as an injectable,” PGT CEO Tim Collard said.
Hercules will be used in Medion’s coryza vaccination program where trials show it has a better safety profile than oil-adjuvated vaccines. At the same time, it also provides good potency and duration of immunity, making it suitable for both broiler and layer birds. The product will be marketed first in Indonesia, then internationally through Medion’s distribution. Hercules will be manufactured in Indonesia in a joint development between PGT and Medion.
PGT holds the global, exclusive rights to Hercules and it is the adjuvant for all PGT’s inactivated vaccines. The adjuvant is also in the regulatory stage in the US in two PGT vaccines (for Salmonella & Eimeria) and in trials with other companies’ vaccines for multiple animal hosts.
ABOUT PACIFIC GENETECH
Pacific GeneTech (www.pacificgenetech.com) develops and commercializes next-generation vaccines and biologics for high unmet or underserved needs in animal health and food safety. PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple pathogen strains and species. The PGT vaccines can be administered orally or by injection in both live and inactivated forms. PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated and DNA vaccines.
PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed Hercules for use in third-party vaccines. Vaccines for other pathogens and host species are under development. PGT is developing other applications for Hercules. PGT, through its affiliate company, PGTx, has programs with collaborators addressing human dysentery and malaria.
Established in 1976 in Indonesia, Medion (www.medion.co.id) is an animal health company focusing on poultry & livestock. The company produces a wide range of high-quality pharmaceuticals and equipment for farming practice. Its product range is supported by laboratory services catered for farmers.
Medion has manufactured poultry vaccines under the Medivac brand since 1993, then later launched a series of herbal products under the brand of Mediherba in 2013. Stringent quality controls are conducted at all levels, from raw materials to finished products, using sophisticated equipment and the latest technology.
Medion strives to continually innovate to meet its customers' needs and improve their capabilities, also focusing on alternatives to antibiotic inputs, including the use of modern farming equipment. Having distributed its products to more than 20 countries in Asia, Africa, and Europe, Medion will actively expand its presence to more countries in the coming years.
Tim Collard, CEO
Tel: +852 2525 8151
Original source: https://www.newswire.com/news/pacific-genetech-adjuvant-technology-approved-for-use-with-medion-21153493